Last Updated: 02/12/2024
Pilot phase for the MAL067 RTS,S immunology ancillary study
Objectives
The Pilot phase of MAL067 study (MAL067 Pilot study) is planned to obtain preliminary data that will facilitate the selection of assays and design of main immune correlates of protection.
Objectives:
- To investigate mechanisms of the RTS,S vaccine-induced protection against malaria
- To identify a correlate of RTS,S vaccine-induced protection
Center for Vaccinology (CEVAC), Ghent University Hospital, Belgium
Centers for Disease Control and Prevention (CDC), United States
Fred Hutchinson Cancer Research Center (FHCRC), United States
GlaxoSmithKline (GSK), United Kingdom
Harvard T.H. Chan School of Public Health (HSPH), United States
Ifakara Health Institute (IHI), Tanzania
Indiana University-Purdue University Indianapolis (IUPUI), United States
Kenya Medical Research Institute (KEMRI), Kenya
Kintampo Health Research Centre (KHRC), Ghana
Laboratory of Malaria and Vector Research (LMVR), NIAID/NIH, United States
New York University (NYU), United States
Noguchi Memorial Institute for Medical Research (NMIMR), Ghana
PATH, United States
Research Institute of Health Sciences (IRSS), Burkina Faso
Seattle Biomedical Research Institute, United States
Swiss Tropical and Public Health Institute (Swiss TPH), Switzerland
Walter Reed Army Institute of Research (WRAIR), United States
Manhiça Health Research Centre (CISM), Mozambique
Jan 2013 — Jun 2017
Related Resources
